Results 241 to 250 of about 331,793 (319)

Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders. [PDF]

Integr Med Insights, 2015
Nash KM, Shah ZA.
europepmc   +1 more source

Cerebrovascular pulsatility in patients with sleep-disordered breathing

, 2012
Alberto R. Ramos, Digna Cabral, David Lee, Ralph L. Sacco, Tatjana Rundek   +4 more
openalex   +2 more sources

Early Levodopa Therapy in Tyrosine Hydroxylase Deficiency

Movement Disorders Clinical Practice, EarlyView.
Claudio M. de Gusmao, Roser Pons, Ganeshwaran H. Mochida, Laura Silveira‐Moriyama, Fernando Kok   +4 more
wiley   +1 more source

Clinical and Radiological Evolution of Idiopathic Normal Pressure Hydrocephalus: A Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The pathophysiology of idiopathic normal pressure hydrocephalus (iNPH) remains poorly understood. While it is commonly accepted that iNPH has an insidious onset, little is known about its preclinical and early stages and its development over time.
David Campo‐Caballero, Elissa Ash, Alfonso Fasano, Davide Martino, Mats Tullberg, Araceli Alonso Canovas, Joachim K. Krauss   +6 more
wiley   +1 more source

[ON CEREBROVASCULAR DISORDERS].

Kita Kanto igaku. Kitakanto medical journal, 1996
G, ONEDA, R, SHIGIYA, J, KAWABUCHI, Y, ISHIDA   +3 more
openaire   +1 more source

Asymptomatic cerebrovascular disorder: Diagnosis and countermeasure. Present state and significance of the brain medical examination (brain medical checkup).

, 1997
篠原 幸人
openalex   +2 more sources

[Cerebrovascular disorders].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2000
openaire   +3 more sources

Origin, diagnosis and treatment of cardiac and cerebrovascular disorder. Recent advances III. Diagnosis 2. Diagnosis of cerebral apoplexy.

, 2000
小林 祥泰
openalex   +2 more sources

Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial

Movement Disorders, EarlyView.
Abstract Background Neuroinflammation contributes to Parkinson's disease (PD) progression and motor dysfunction. Allogeneic human mesenchymal stem cells (allo‐hMSCs) may reduce neuroinflammation and improve motor symptoms. Objectives To evaluate the efficacy of repeated intravenous doses of 10 × 106/kg allo‐hMSCs in improving motor symptoms in patients
Mya C. Schiess, Jessika Suescun, Juan D. Martinez‐Lemus, Charles Green, Tia S. Thomas, Mohammad Shahnawaz, Emily Tharp, Nikunj B. Satani, Jerome G. Saltarrelli, Christopher Adams, Marie‐Francoise Doursout, Vanessa Thyne, Rula Abuamouneh, Elsa M. Rodarte, Sean I. Savitz, Timothy M. Ellmore   +15 more
wiley   +1 more source